These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid. Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598 [TBL] [Abstract][Full Text] [Related]
26. Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. Kitagawa Y; Okumura K; Watanabe T; Tsukamoto K; Kitano S; Nankinzan R; Suzuki T; Hara T; Soda H; Denda T; Yamaguchi T; Nagase H Sci Rep; 2019 Aug; 9(1):11346. PubMed ID: 31383871 [TBL] [Abstract][Full Text] [Related]
27. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013 [TBL] [Abstract][Full Text] [Related]
28. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225 [TBL] [Abstract][Full Text] [Related]
29. Highly specific detection of KRAS single nucleotide polymorphism by asymmetric PCR/SERS assay. Lyu N; Rajendran VK; Li J; Engel A; Molloy MP; Wang Y Analyst; 2021 Sep; 146(18):5714-5721. PubMed ID: 34515700 [TBL] [Abstract][Full Text] [Related]
30. Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patients. Wang D; O'Rourke D; Sanchez-Garcia JF; Cai T; Scheuenpflug J; Feng Z BMC Cancer; 2021 Jul; 21(1):797. PubMed ID: 34243735 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000 [TBL] [Abstract][Full Text] [Related]
32. Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. Zonta E; Garlan F; Pécuchet N; Perez-Toralla K; Caen O; Milbury C; Didelot A; Fabre E; Blons H; Laurent-Puig P; Taly V PLoS One; 2016; 11(7):e0159094. PubMed ID: 27416070 [TBL] [Abstract][Full Text] [Related]
33. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F; Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295 [TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795 [TBL] [Abstract][Full Text] [Related]
35. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085 [TBL] [Abstract][Full Text] [Related]
36. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403 [TBL] [Abstract][Full Text] [Related]
37. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389 [TBL] [Abstract][Full Text] [Related]
39. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations. Poole JC; Wu SF; Lu TT; Vibat CRT; Pham A; Samuelsz E; Patel M; Chen J; Daher T; Singh VM; Arnold LJ PLoS One; 2019; 14(10):e0223112. PubMed ID: 31581267 [TBL] [Abstract][Full Text] [Related]
40. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy. Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]